Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Galectin Therapeutics" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Galectin Therapeutics for you to read. Along with our medical data and news we also list Galectin Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Galectin Therapeutics Companies for you to search.
NORCROSS, Ga., Aug. 25, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announces interim results from an exploratory, open-label, Phase 2a clinical trial with...
Roth Capital Partners resumed coverage of Galectin Therapeutics (NASDAQ:GALT) with a “buy” rating and $3 price target. The stock closed at $1.52 on Friday. “In our opinion, Phase 1 data demonstrated Galectin’s GR-MD-02’s positive effect on NASH fibrosis biomarkers,” writes analyst Sa’ar Yaniv. “While we are expect that the 30-patient placebo-controlled Phase 2 study will [&...
Dr. Traber to speak on Galectin Therapeutics’ Development of GR-MD-02 for treatment of human disease Read more...
Galectin Therapeutics Inc. announced enrollment is complete for its phase 2 NASH-FX trial investigating GR-MD-02, a complex carbohydrate drug that targets galectin-3, for the treatment of nonalcoholic steatohepatitis and advanced fibrosis.The study, which will be led by Stephen A. Harrison, MD, FACP, FAASLD, professor of medicine at the Uniformed Services University of the Health Sciences, San Ant...
Galectin Therapeutics Inc (NASDAQ:GALT) won’t pursue GR-MD-02 as a drug for psoriasis after patients in a small trial did not show the required improvement. The drug developer added, however, that the results did give it encouragement for its liver fibrosis program, which is the drug’s primary focus. Galectin started the small study after a patient taking the drug in a tr...
Galectin Therapeutics has completed enrollment in its phase 2 clinical trial of GR-MD-02 in patients with non-alcoholic steatohepatitis (NASH) with advanced fibrosis (stage 3).
Galectin-3 is a unique member of chimera type galectins and is involved in a large number of disease processes and...
Galectin Therapeutics (NASDAQ:GALT) has completed patient recruitment in its Phase 2 clinical trial with GR-MD-02 in patients with non-alcoholic steatohepatitis (NASH) with cirrhosis, the NASH-CX trial. The company expects to report the topline results of the trial in December 2017. “We are pleased that patient recruitment in our NASH-CX trial was completed ahead of our original […]
The new study examines the biomechanics of galectin-3's interaction with glycosaminoglycans (GAG) and proteoglycans. Tarun Dam, an associate professor of chemistry at Michigan Technological University, led the study. The other co-authors of the paper are graduate students Melanie Talaga, Ni Fan, ...
* Completion of enrollment in phase 2 clinical trial with GR-MD-02 in patients with NASH with advanced fibrosis
Top-line data from NASH-FX trial in NASH patients with advanced fibrosis expected to be reported by the end of September Australian patent allowance strengthens global intellectual property franchise NORCROSS, Ga., Aug. 09, 2016 (GLOBE NEWSWIRE) Read more...
* Says announces results from 12-week extension of phase 2A psoriasis clinical trial - SEC Filing
The ultimate impediment to a cure for HIV infection is the presence of latent, HIV-infected cells, which can reawaken and produce new virus when antiretroviral drug therapy is stopped. These latent, HIV-infected cells are untouched by antiretroviral therapy and are unseen by the immune system. Moving medicine closer to a cure for HIV, scientists at Blood Systems Research Institute (BSRI), the Univ...
Patient sample, cell culture and mouse studies suggest inhibiting
The ultimate impediment to a cure for HIV infection is the presence of latent, HIV-infected cells, which can reawaken and produce new virus when antiretroviral drug therapy is stopped.
Seres Therapeutics, a microbiome therapeutics platform company, and Emulate, a private firm commercializing the Organs-on-Chips technology, announced a new collaboration.
NASH, a fatty liver disease, has grown in prevalence, with some saying it will replace hepatitis C as the main cause of liver transplantation by 2020.
US biotech firm BIND Therapeutics, a developer of targeted and programmable therapeutics called Accurins,…